mTOR inhibitors (temsirolimus, everolimus) have also been added in the armamentarium against RCC targeting cancer progress and angiogenesis, while immune checkpoint inhibitors against PD-1 and CTLA4, such as nivolumab, ipilimumab are recently tested in various combinations to achieve durable responses and improve the disease-free survival. This evidence concerns the gene CTLA4 and renal cell adenocarcinoma.